| Literature DB >> 24465543 |
Senthil Selvaraj1, Durga S Borkar2, Vinay Prasad3.
Abstract
BACKGROUND: News coverage of medical research is followed closely by many Americans and affects the practice of medicine and influence of scientific research. Prior work has examined the quality of media coverage, but no investigation has characterized the choice of stories covered in a controlled manner. We examined whether the media systematically covers stories of weaker study design.Entities:
Mesh:
Year: 2014 PMID: 24465543 PMCID: PMC3894978 DOI: 10.1371/journal.pone.0085355
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of Clinical Investigations Covered by High Circulation Newspapers and High Impact Medical Journals.
| Characteristic | Investigations from High Circulation Newspapers (N = 75) | Investigations from High Impact Medical Journals (N = 75) | P-value |
| Journal impact factor | 5.4 (4.1–30.0) | 30.0 (16.7–33.8) | <0.001 |
| Participants, n | 1034 (112–17408) | 1901 (412–32608) | 0.14 |
| Pharmaceutical funding, n (%) | 5 (7) | 12 (16) | 0.12 |
| Randomized controlled trials, n (%) | 13 (17) | 26 (35) | 0.016 |
| Observational studies, n (%) | 56 (75) | 35 (47) | <0.001 |
| Studies assessing mortality, n (%) | 17 (23) | 19 (25) | 0.70 |
| Cross-sectional studies, n (%) | 45 (60) | 22 (29) | <0.001 |
| Length of follow-up in longitudinal studies, y | 1.80 (0.42–6.00) | 1.00 (0.21–4.00) | 0.22 |
| Study design rating, n (%) | 0.003 | ||
| • 1 | 13 (17) | 30 (40) | |
| • 2 | 5 (7) | 0 (0) | |
| • 3 | 51 (68) | 38 (51) | |
| • 4 | 2 (3) | 1 (1) | |
| • 5 | 4 (5) | 6 (8) |
Presented as median (25th–75th percentile) because data was not normally distributed.
Refer to text for details of quality scale.
Figure 1Distribution of study design ratings for clinical investigations from the media and medical journals.
(A) The media covers inferior quality study designs than those published in (B) high impact medical journals (p = 0.003; see text for details).
Subgroup Analysis of Observational Studies and Randomized Controlled Trials Stratified by Initial Source of Investigation.
| Characteristic | Observational Studies (N = 91) | Randomized Controlled Trials (N = 39) | ||||
| Newspapers (N = 56) | Medical Journals (N = 35) | P-value | Newspapers (N = 13) | Medical Journals (N = 26) | P-value | |
| Journal impact factor | 5.4 (3.9–14.5) | 16.7 (16.7–30.0) | <0.001 | 11.5 (4.7–53.3) | 33.8 (30.0–53.3) | 0.09 |
| Participants, n | 1984 (173–57491) | 21136 (1655–264758) | 0.029 | 420 (84–1020) | 568 (312–1723) | 0.30 |
| Pharmaceutical funding, n (%) | 3 (6) | 1 (3) | 0.64 | 2 (15) | 10 (38) | 0.27 |
| Studies assessing mortality, n (%) | 13 (23) | 9 (26) | 0.79 | 3 (23) | 8 (31) | 0.72 |
| Cross-sectional studies, n (%) | 40 (71) | 11 (31) | <0.001 | 2 (15) | 0 (0) | 0.11 |
| Length of follow-up in longitudinal studies, y | 5.50 (2.50–10.13) | 3.50 (0.08–10.10) | 0.33 | 0.42 (0.23–1.00) | 1.00 (0.25–1.00) | 0.36 |
Presented as median (25th–75th percentile) because data was not normally distributed.